Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Case Report: Effective use of rituximab in children with steroid-resistant/dependent idiopathic pulmonary hemosiderosis: description of two cases and literature review.

Created on 13 Oct 2026

Authors

Sha Li, Tinghua Liu, Rongqiong Ou, Haiyan Wang, Bihong Zhang, Weiping Tan

Published in

Frontiers in pediatrics. Volume 14. Pages 1944579. Epub Sep 28, 2026.

Abstract

Idiopathic pulmonary hemosiderosis (IPH) is a rare, chronic, and potentially life-threatening disorder predominantly affecting the pediatric population. While most patients respond to conventional immunosuppressive therapy, management of steroid-resistant/dependent cases remains challenging. This study aims to evaluate the efficacy and safety of rituximab (RTX) in the treatment of steroid-resistant/dependent IPH in children.
We report two pediatric cases of steroid-resistant/dependent IPH who were admitted to our institution. Both patients presented with severe, recurrent diffuse pulmonary hemorrhage and demonstrated poor response to conventional therapy including high-dose corticosteroid pulse therapy and combination immunosuppressants. Clinical data, laboratory findings, radiographic features, treatment regimens, and outcomes were collected and analyzed.
Both patients exhibited steroid resistance or dependence with persistent or recurrent pulmonary hemorrhage despite aggressive conventional immunosuppression. Following RTX administration, rapid and sustained hemorrhage control was achieved in both cases. Clinical remission was maintained over follow-up periods of 6 months for both patients, with successful corticosteroid tapering and no significant infusion-related adverse events observed. No disease relapse occurred during the follow-up period.
Rituximab appears to be an effective and well-tolerated rescue therapy for steroid-resistant/dependent IPH in children, offering sustained hemorrhage control and facilitating corticosteroid-sparing. Given the limited existing literature on RTX application in IPH management, this report offers a novel therapeutic approach for steroid-resistant/dependent IPH cases.

PMID:
42865552
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement